TMCnet News
Downgrade Alert for Endo Pharmaceuticals (ENDP)Feb 07, 2013 (SmarTrend(R) Upgrades/Downgrades via COMTEX) -- Endo Pharmaceuticals (NASDAQ:ENDP) was downgraded from Sector Perform to Underperform at RBC Capital today. The stock closed yesterday at $30.66 on volume of 2.3 million shares, below average daily volume of 2.6 million. Over the past year, Endo Pharmaceuticals has traded in a range of $25.00 to $44.53 and closed yesterday at $31.00, 24% above that low. The 200-day and 50-day moving averages have moved 0.25% lower and 0.75% higher over the past week, respectively. Endo Pharmaceuticals Holdings Inc. is a specialty pharmaceutical company with products that provide pain management. The Company researches, develops, produces, and markets both branded and generic pharmaceuticals. Endo's products include Percocet, Percodan, and Lidoderm. Endo Pharmaceuticals (NASDAQ:ENDP) has potential upside of 7.4% based on a current price of $31.00 and analysts' consensus price target of $33.31. The stock should discover initial support at its 200-day moving average (MA) of $30.27 and subsequent support at its 50-day MA of $27.56. SmarTrend is monitoring the recent change of momentum in Endo Pharmaceuticals. Please refer to our Company Overview for the results of our proprietary technical indicators that have been scanning shares of Endo Pharmaceuticals in search of a potential trend change. Write to Chip Brian at [email protected] --------------------------------------------------------------------------------------------- SmarTrend analyzes over 5,000 securities simultaneously throughout the trading day and provides its subscribers with trend change alerts in real time. To get a free trial of our trading calls and maximize your trading results, please visit http://www.MySmarTrend.com Get exclusive, actionable insight into how the market is expected to trend prior to market open with our free morning newsletter. Sign up at: http://www.MySmarTrend.com/signup |